The liver-type and muscle-type isozymes of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase are encoded by one gene that uses two alternative promoters. We have identified cis-acting sequences and protein-binding sites on the liver-type promoter. Transfection assays with deleted promoters showed that maximal promoter activity is contained within 360 bp upstream of the cap site. DNase I footprinting experiments with liver and spleen nuclear extracts and with purified proteins revealed several protein-binding sites in this region. These included four binding sites for nuclear factor I, one site that contains an octamer consensus but showed a liver-specific footprint pattern, two liver-specific protein-binding sites, and one poly(dG)-containing binding site. Transfection of cells of hepatic origin suggested that all these sites except one are involved in transcriptional regulation. The region between -360 and -2663 contained an element that functioned as a silencer in a nonhepatic c...
Fructose-2,6-bisphosphate is the most potent stimulator of 6-phosphofructo-1-kinase, a key enzyme of glycolysis. The synthesis and degradation of fructose-2,6-bisphosphate are catalyzed, respectively, by 6-phosphofructo-2-kinase (PFK-2) and fructose-2,6-bisphosphatase (FBPase-2). In liver these two activities are borne by separate domains of a homodimeric protein which is therefore one ofthe rare bifunctional enzymes. Several PFK-2/FBPase-2 isozymes whose expression differs depending on the tissue have been described (for a review, see reference 12) . The molecular structure of the isozymes is unknown, except for the liver (L) and muscle (M) isozymes. We have indeed cloned a 55-kb rat gene, containing 15 exons, that encodes the L and M isozymes by alternative use of two different promoters, referred to as L and M promoters. The L and M mRNAs share the same 13 exons. They have an additional exon which is specific for either the M isozyme (first exon of the gene) or the L isozyme (second exon of the gene). Thus, the L promoter region lies between these two exons (7) . The concentration of L mRNA is highest in liver, but this mRNA is detectable in other tissues (5) . Its concentration in liver is regulated by hormones and is increased by insulin in diabetic rats (3) and by triiodothyronine (T3) in hypothyroid rats (31) . Transcription of the liver mRNA is also increased by glucocorticoids in adrenalectomized rats (16) . The PFK-2/ FBPase-2 L promoter is therefore an interesting model for studying the tissue-specific and hormonal regulation of transcription. We have delineated here the 5'-flanking sequences that influence promoter activity by transfecting hepatoma cells and isolated normal hepatocytes as well as pituitary tumor cells with L promoter mutants linked to a reporter gene. The factors that bind to these sequences have been identified by in vitro DNase I footprinting and band-shift assays. medium supplemented with 5% fetal calf serum (FCS), 1 ,uM dexamethasone, 1 ,uM T3, and 10 nM insulin. Twenty-four hours before transfection, 1.5 x 106 ATIII-SV40 cells per 60-mm dish were plated in Dulbecco's modified Eagle's medium (DMEM) plus 5% FCS without addition of hormones. Rat pituitary tumor GC cells were grown as monolayers in Ham's F12 medium supplemented with 10% FCS. Rat hepatoma Fa32 cells and human cervix carcinoma HeLa cells were grown as monolayers in DMEM supplemented. respectively, with 10 and 5% FCS.
Primary cultures of hepatocytes isolated from rats fasted for 72 h were prepared as previously described (8) DNA-binding assays. Nuclear extracts from rat liver and spleen were prepared by the method of Gorski et al. (9) , except that the final dialysis was performed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 7.6)-100 mM KCl-10 mM MgCl2-1.5 mM dithiothreitol-0.2 mM EDTA-15% glycerol. Final protein concentration ranged from 3 to 6 mg/ml. Whole extracts from GC, HeLa, and Fa32 cells were as previously described by Manley (15 (20) . The 3' end of all the deleted promoter constructs corresponds to the AluI site at +87 (+ 1 is the major cap site [7] ) cloned in the SmaI site of the polylinker. Only pPLLuc36 contains an additional KpnI site and a blunt-ended BanII site in the polylinker between the promoter and the luciferase gene. The numbering of the pPLLuc plasmids corresponds to the position of the restriction site used to make the 5' deletion: BanIl, -36; BstNI, -71; SpeI, -111; DpnI, -138; StuI, -219; Alul, -237; AccI, -360; HpaII, -444; EcoRV, -809; and HindIll, -2663. All these sites were cloned in the blunt-ended Sall site of the polylinker, with the exceptions of pPLLuc2663, in which the 5' end is cloned in the HindIII site of the polylinker, and of pPLLuc360 and pPLLuc36, in which the 5' end is cloned in the SmaI site of the polylinker. pPFKLuc2663 contains the HindIII (-2663)-HaeIII (+4) L promoter fragment cloned in the HindIII and SmaI sites of pXP2. pTZP2663 contains the HindIII-BglIll fragment, which contains the -2663 to +4 promoter region, of pPFKLuc2663 cloned in the HindIII-BamHI sites of pTZ19R (Pharmacia).
RESULTS
Binding of nuclear proteins to the PFK-2/FBPase-2 L promoter. As shown below, we found that full promoter activity in transfection experiments is conferred by the 360 bp upstream from the cap site. To delineate the functionally important promoter regions, we searched for potential protein-binding sites in this 360-bp fragment. DNase I footprinting experiments were performed on an AccI (-360)-BglII (+4) fragment isolated from pPFKLuc2663 and end labeled on the noncoding strand at the BglIl site. Three footprints were visualized in the presence of liver nuclear extract ( Fig.  1A ): footprint I, from -43 to -66; footprint II, from -78 to -102; and footprint III, from -114 to -132. Protection was not complete at the downstream border (-78) of footprint II (see Fig. 3 , compare lanes 1 and 2). Footprints II and III were interrupted by a DNase I-hypersensitive site (arrows in Fig. 1A ). On the coding strand, the coordinates of footprints I, II, and III were, respectively, -42 to -63, -79 to -98, and -112 to -128 (Fig. 1B) . Note that the hypersensitive sites (arrows in Fig. 1B ) in footprints II and III were again observed.
To determine whether these footprints were liver specific, we performed footprinting experiments with spleen nuclear extracts. With these extracts three footprints with the same coordinates as with the liver extract were observed (Fig.  1A) . However, footprints I and II were detected at higher protein concentrations with spleen than with liver extract, and the hypersensitive site in footprint III was never observed with spleen extract.
The same region of the promoter, i.e., the AccI (-360)-XhoI (+4) fragment of pTZP2663, was labeled at the other end on the coding strand (AccI site). This enabled us to visualize three additional footprints with liver extract: foot- print IV, from -196 to -213, with a DNase I hypersensitive site at -195 (arrow); footprint V, from -219 to -231; and footprint VI, from -269 to -281 (Fig. 1C) . The downstream boundary of footprint VI was ill-defined under these conditions. We never observed total protection against DNase I in the footprint V region, even at higher protein concentrations (not shown). On the noncoding strand, the coordinates of footprints IV, V, and VI were, respectively, -200 to -216, -225 to -237, and -267 to -283 (Fig. 1D) .
With spleen extracts, DNase I protection experiments using the same probe showed a different picture. Footprint IV was replaced by hypersensitive sites at -195 and -211 (arrows in Fig. 1C ). Footprint V was absent, and the region from -269 to -295 that overlaps with footprint VI was protected (Fig. 1C) . A summary of the footprinting data on the PFK-2/FBPase-2 L promoter is shown in Fig. 2 .
Footprints I and II are due to NF-I-related proteins. Examination of the nucleotides corresponding to footprints I and II (Fig. 2) shows that each contains on the coding strand a TGGC sequence (-58 and -95) that is found (23) in the palindromic binding motif TGGC/ANNNNNGCCAA for nuclear factor I (NF-I). It is known that half of this palindrome suffices to bind NF-I (22) . We therefore performed a footprinting experiment with liver nuclear extract (Fig. 3) in the presence of a competing oligonucleotide, 5'-ATTITTlGi.CTACAAG.CCAATATGAT-3', that contains an NF-Ibinding site (underlined). Addition of this NF-I oligonucleotide inhibited footprints I and II (Fig. 3, lanes 3 and 4) . This effect was specific, since footprint III was not prevented and because an unrelated oligonucleotide, 5'-GTAGGCCCACGT GACCGGG-3', which contains an upstream stimulatory factor (USF)-binding site (underlined), had no effect on footprints I, II, and III (Fig. 3, lane 5) . If footprints I and II are due to NF-I, then they should also be visualized by using purified NF-I instead of nuclear extracts. We therefore incubated the DNA probe with purified vNFIBD which corresponds to the N-terminal 240 amino acids, i.e., the DNA-binding domain, of liver NF-I (10). vNFIBD produces footprints identical to those seen with intact NF-I (6). A footprint (Fig. 3 smaller size of vNFIBD compared with NF-I, which might not bind at the site because of steric hindrance.
vNFIBD produced another footprint containing two hypersensitive sites (arrows) located from -225 to -255 and therefore overlapping with footprint V (Fig. 3, lane 10) . This region contains the half NF-I palindromic motif TGGA at -242 (Fig. 2) . This NF-I site was not detected with liver nuclear extract, presumably because of low affinity or be- (Fig. 1A) . As far as we know, such a hypersensitive site has never been described in footprints obtained with any octamer factor. Furthermore, OTF-I purified from HeLa cells produced on our promoter fragment a footprint III with the same boundaries as with liver or spleen nuclear extract but with no hypersensitive site (Fig. 3, lane 13) . The hypersensitive site therefore seems to be liver specific. Indeed, we detected it with rat hepatoma Fa32 cell extract, but not with rat pituitary GC cell extract (not shown). Proteins involved in footprints IV, V, and VI. Footprint IV was detected with liver but not with spleen nuclear extract (Fig. 1C) . The sequence on the noncoding strand (-196) C'lI-TlGAAATTIGATTT-CAAAGC (-216) resembles (underlined) the human transferrin gene promoter sequence 5'-C2JJI`GACCfTlXAGCCCAG-3', which is known to bind the transcription factor Tf-LF2 (21). The footprint IV region also contains on each strand a sequence GCTTTJ.XGAAAI that resembles (underlined) the core sequence TCTIIII2GACCI found in the binding sites for the liver-specific factors Tf-LF1, Tf-LF2, and LF-A1 (21) . The central part of footprint IV and the hypersensitive site at -195 persisted when the assay was performed with a liver extract heated at 65°C for 5 min (Fig. 1C) . Since Tf-LF2, but not Tf-LF1 or LF-A1, is thermostable (21), footprint IV might be due to Tf-LF2 or to a related protein.
Footprint V, always weak with liver nuclear extract and absent with spleen nuclear extract, contains the sequence (-236) TTAAIGJ7CIAAITAGGC (-219), which is similar (underlined) in its central part to the 5'-GGTAI-GAITTGTAAIGGTA-3' sequence of the mouse albumin gene known to bind transcription factors DBP and CIEBP (18) . The latter is heat stable. Since heated liver nuclear extract (65°C for 5 min) did not produce footprint V (Fig.  1C) , the participation of C/EBP in footprint V is unlikely. The disappearance of footprint V on heating might explain why the boundaries of footprint IV changed under those conditions (Fig. 1C) , since the lack of footprint V is expected to modify DNase I sensitivity in this region. Identification of the protein responsible for footprint V with DBP is only tentative, since the thermosensitivity of DBP has not been reported and this footprint also contains a palindrome, GCNIAAINNNNNNATTANGC, that bears no relationship to the DBP-binding site on the albumin gene.
Footprint VI corresponds to a poly(dG) stretch. It was detected with liver and spleen extracts but extended further upstream to -295 with spleen extract (Fig. 1C) . The sequence between -281 and -295 is T rich. To our knowledge, no poly(dT)-binding site for a spleen-specific factor has been reported on another gene. With rat pituitary GC cell extracts and with HeLa cell extracts, the boundaries of footprint VI were identical to those seen with liver extract (not shown). The footprint observed with liver extract persisted after the extract was heated at 65°C for 5 min, in which case the boundaries were better defined (Fig. 1C) .
Delineation of transcriptional regulatory elements within the PFK-2/FBPase-2 L promoter. To localize the regulatory elements of the PFK-2/FBPase-2 L promoter, we performed transfection experiments in the ATIII-SV40 hepatoma cell line. The L promoter (from -2663 to +87) and 5' deletions thereof were cloned upstream of the luciferase-coding sequences. The constructs were cotransfected with pRSV,gal as an internal control, and the results of luciferase activity were normalized for P-galactosidase activity.
The results are shown in Fig. 5 . It can be seen that all the transcriptionally active sequences were located within the 360 bp upstream of the cap site, since addition of nucleotides -360 to -2663 did not modify promoter activity significantly. The 5' deletions, performed within the proximal 360 bp and chosen to remove the footprinted sequences described above, showed that discrete regions had a clear-cut effect on transcription. Basal promoter activity (pPLLuc36) was increased twofold by the addition of the sequence that includes footprint I (pPLLuc7l) and threefold by the addition of the sequence that also contains the footprint II region (pPLLuc111). A further increase in transcriptional activity was observed with pPLLuc138. This construct, which contains the footprint III region, had an activity two-to threefold higher than that seen with pPLLuclll. Addition of the sequence up to -219, which includes the liver-specific footprint IV (pPLLuc219), further increased transcription 1.5-fold. No further enhancement of transcriptional activity was observed with pPLLuc237, which contains the footprint V region. Finally, addition of the sequence from -237 to -360 (pPLLuc360), which includes footprint VI, yielded the highest promoter activity obtained in our assay system.
To investigate the effects of L promoter deletions in isolated hepatocytes, we transfected these cells with some of our pPLLuc constructs (Table 1) . With pPLLuc36, pPLLuc7l, pPLLuclll, and pPLLuc138 we observed effects comparable with those seen in transfection experiments performed on ATIII-SV40 cells. Basal promoter activity (pPLLuc36) increased two-to threefold on addition of the sequence that includes footprint I (pPLLuc7l). Activity was again doubled when the sequence containing footprint II was present in the construct (pPLLuclll). Addition of the sequence that includes footprint III (pPLLuc138) further stimulated (twofold) transcriptional activity. Unlike ATIII-SV40 cells, sequences upstream of -138 did not increase promoter activity in isolated hepatocytes. This may be consistent with our observation that the viability of isolated hepatocytes was severely affected on transfection. Since this could affect transfection, luciferase activity (test plasmid) was corrected for P-galactosidase activity (control plasmid). The whole series of constructs was tested concomitantly in four independent experiments. To correct for variation between experiments (see Materials and Methods), a value of 100o was assigned in each experiment to the activity of the construct that gave the highest ratio of luciferase to 3-galactosidase. The data shown are means + standard errors of the mean of these normalized values.
some cellular functions before others, one possibility is that the factors that bind upstream of -138 are more readily affected than those that bind downstream. Another possibility is that the activity of sequences upstream of -138 depends on factors, e.g., the liver-specific factor responsible for footprint IV, that are no longer present or active in cultured hepatocytes. Indeed, dedifferentiation is a known feature of hepatocytes in culture.
Finally, to analyze the activity of the L promoter in a nonhepatic cell line, we performed transfection experiments in rat pituitary GC cells. pPLLuc360, which produced a maximal activity in cells of hepatic origin, yielded in GC cells 1,193 + 11 relative units (mean + standard error of the mean for three experiments; luminescence units corrected for P-galactosidase activity). pPLLuc2663, which also produced maximal activity in cells of hepatic origin, yielded in GC cells 261 ± 28 relative units, i.e., a value 4.5-fold lower than that produced by pPLLuc360. This indicates that in GC cells the -360 to -2663 region functions as a negative regulatory element. This is consistent with the fact that we The first two footprints upstream of the cap site were assigned to NF-I. Our DNase I and gel-shift experiments with purified NF-I suggested the presence of two additional NF-I-binding sites; one was between footprint I and the cap site, and another was just upstream of footprint V. NF-I actually refers to a family of proteins (25, 27) originating from alternative splicing of the same transcript (27) or from different genes (24) . These proteins contain a highly conserved N terminus and a variable C terminus (17) . Our transfection experiments demonstrated that the proteins which bind between footprint III and the TATA box, i.e., most likely NF-I, together stimulate transcription threefold. NF-I has been implicated in the transcriptional control of genes expressed in the liver (22) . Thus, NF-I is a good candidate for participating in the control of transcription from the L PFK-2/FBPase-2 gene promoter in vivo.
Another protein that appears to mediate transcriptional stimulation of the L promoter is the one involved in footprint III. This footprint contains a sequence known to bind a family of octamer proteins. These include the ubiquitous Oct-i factor, the lymphocyte-specific Oct-2A and Oct-2B factors, and the factors Oct-3 to Oct-10, which are detected in various mouse tissues and embryo at different stages of development (30) . The Oct factors are transcriptional acti-100 MOL. CELL. BIOL.
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vators, but in F9 cells the octamer factor NF-A3, which is probably identical to Oct-4 (29), can mediate repression (13) . The PFK-2/FBPase-2 L promoter octamer sequence stimulated transcription more than twofold. The footprint pattern seen with liver extract differed from that obtained with purified HeLa Oct-i. One interpretation is that the liver octamer protein differs from Oct-i. If so, these two proteins should, however, be very similar, since in band-shift assays an immunoglobulin heavy-chain gene fragment bearing the octamer sequence is retarded identically with a liver extract and with purified HeLa Oct-i (30) . Another interpretation is that the liver-specific pattern of footprint III results from the binding of a complex consisting of Oct-i associated with another liver protein(s). In this case, the sequences located near the octamer consensus on the PFK-2/FBPase-2 L promoter could play a role in the formation of the postulated Oct-i-protein complex, since only one complex was visualized in the band-shift experiment mentioned above with the immunoglobulin promoter fragment.
A third type of factor that trans-activates the promoter studied here is the one responsible for the liver-specific footprint IV. We have tentatively assigned this footprint to Tf-LF2. The sequence protected contains the remarkable palindrome 5'-GCTTTGAAATNNAl-TCAAAGC-3'. This palindrome is poorly conserved in the Tf-LF2-binding site of the human transferrin gene promoter sequence 5'-AGTCT GTC l-l-lGACCITGAGCCCAGCT-3'. Since Ochoa et al. (21) did not mention that Tf-LF2 binding required a palindrome, further study is in order to determine whether this palindrome is the actual Tf-LF2 consensus or whether footprint IV is due to another protein.
The sequence upstream of footprint IV conferred 25% additional activity to the L promoter. This activity was due to the region between -219 and -360. We identified in this region a binding site for a DBP-like protein (footprint V), the 5' side of which overlaps with an NF-I-binding site, and a binding site for a heat-stable poly(dG)-binding protein. Assuming that the NF-I site (-230 to -242) is lost in the pPLLuc237 construct, then eith'er NF-I or the poly(dG)-binding protein or both are candidates for mediating transcriptional stimulation conferred by the region from -219 to -360. Clark et al. (2) have listed the longest poly(dG) stretches contained in polymerase II-transcribed genes. The same group of investigators detected poly(dG)-binding proteins in several tissues (14) but did not look for the presence of such proteins in liver. Although the function of these proteins is unknown, the erythrocyte-specific poly(dG)-binding BGP1 factor seems to be involved in nucleosome positioning, without having a transcriptional activity (14) . Further work is needed to determine the role of the heat-stable poly(dG)-binding factor that accounts for footprint IV. It is known that not all specific protein-DNA interactions can be identified by footprinting. Thus, factors other than the poly(dG)-binding protein or NF-I which were not detected here could be involved in the activity of the sequence upstream from footprint V. For instance, the sequence (-261) TGAACCT (-255), which was not footprinted in our experiments, is a motif reported to bind the liver-specific trans-acting factor LF-Ai (21) .
Expression of the PFK-2/FBPase-2 liver isozyme is controlled by insulin (3) and by thyroid (31) and glucocorticoid hormones. The latter stimulate transcription of the isozyme (16 
